Longeveron receives FDA clearance for Phase 2 trial of laromestrocel in pediatric dilated cardiomyopathy

Longeveron Inc.

FDA approved IND for a Phase 2 pivotal registration study of laromestrocel for pediatric DCM.
Trial initiation anticipated in first half of 2026.
Nearly 40% of children with DCM require heart transplant or die within 2 years of diagnosis.
Allogeneic mesenchymal stem cell therapy may address anti-inflammatory and pro-vascular mechanisms.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.